Labiotech.eu

News and Trends 29 Sep 2016

Boehringer buys a €210M ticket to Virus-based Immuno-Oncology

Boehringer Ingelheim has signed a deal with ViraTherapeutics, an Austrian start-up that focuses on the development of oncolytic virus therapies. If everything goes well, the big Pharma could acquire the Biotech start-up after completion of Phase I trials. Boehringer Ingelheim has its eye on ViraTherapeutics’ oncolytic virus platform. The young Biotech’s technology establishes a novel treatment approach that […]

September 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Sep 2016

Interview: This Biotech Could Have the First HIV Cure on the Market

InnaVirVax is one of the most advanced companies in the race to develop an HIV cure. At the SACHS Conference in Basel, we had the opportunity to pick the brain of the CEO, Joël Crouzet, about his company’s progress. Last week, we reviewed progress in biotech towards an HIV cure, which could hit the market […]

September 29, 2016 - 1 minutemin - By Evelyn Warner

News and Trends 29 Sep 2016

Titans in Gene Therapy and TCRs make a Massive Deal

Medigene has licensed a few candidates from its TCR platform to one of the Boston ‘it’ biotechs in a deal totaling around €1B. By partnering with bluebird bio, Medigene is reestablishing itself as a leader in immuno-oncology. Founded over 20 years ago, Medigene has risen to the top of the European biotech scene with a […]

September 29, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 29 Sep 2016

Debunking the Immuno-Oncology Hype: is it as good as it sounds?

CAR-T therapies have gained plenty of attention lately by promising to end cancer with a one-off treatment. But all that glitters is not gold; experts remind us it is important to be critical about the immuno-oncology hype. Immuno-oncology has become all the rage lately, and the hype has led to some major investments, acquisitions, deals and partnerships. It seems […]

September 29, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Sep 2016

Biotech is one of the biggest Employers in Europe

As part of the European Biotech Week, EuropaBio shared yesterday a study revealing that Industrial Biotech has created 486,000 full-time jobs and contributes €31.6B to the EU. This new data emphasizes the huge role that Biotech plays on the continent’s economy. The biotech industry was in the spotlight this week at the European Parliament, where the report was presented, and it […]

September 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Sep 2016

Little Biotechs manoeuvre to outfox Big Pharma in Immuno-Oncology

Giants like BMS and GSK have been throwing all the money they can at developing immuno-oncological treatments. In twin deals, four smaller companies are forging new paths to cure cancer with the human immune response. A pair of agreements among immuno-oncology biotechs have been made in attempts to outflank big pharma competition. In Scandinavia, Orion will fund […]

September 28, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 28 Sep 2016

ITW: Prexton Therapeutics CEO explains Development of new Parkinson’s Drug

For our first interview at the SACHS Conference in Basel yesterday, I met with François Conquet, founder and CEO of Prexton Therapeutics. His company’s treatment for Parkinson’s Disease just passed Phase I with flying colors. Prexton Therapeutics, based in Switzerland, has been focused on discovering new small molecules to treat Parkinson’s, and one of them, an mGluR4 positive […]

September 28, 2016 - 1 minutemin - By Evelyn Warner

synapses neurons alzheimers Bruce Rolff fi

News and Trends 27 Sep 2016

Another “Almost” against Alzheimers: Lundbeck’s Phase III Flop

Alzheimer’s Disease is the most common form of dementia, affecting 15M people across the world. With the most recent failure of idalopirdine, a cure will remain elusive for now. As Derek Lowe observes, “Alzheimers therapies have, for the most part, been a cliff over which people push bales of money.” Unfortunately, the late-stage failure of […]

September 27, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 26 Sep 2016

A Colony from a single-cell? All possible with Takara Bio

Induced pluripotent stem cells were discovered back in 2006. Since then, they have become a valuable new source of pluripotent cells for research and therapy. And thanks to gene editing technologies, researchers can induce a single mutation in those cells for a broad range of applications. However, the main challenge is the proliferation of a single-cell with […]

September 26, 2016 - 3 minutesmins - By Jerome Topsent

News and Trends 26 Sep 2016

It’s Biotech Week! What’s Up in Europe?

The annual celebration of biotech has started! From today through this Sunday, October 2nd, a continent-wide festival, Biotech Week, is happening as part of a larger global affair. Check out the event program and Invest Europe’s infographic on what’s up in Europe! EuropaBio has kicked off the European instalment of global Biotech Week, a week-long series […]

September 26, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 26 Sep 2016

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers

It’s not the $700M headlines imply, but AC Immune is winding up to make a splashy IPO of €52.5M to establish itself in the Alzheimer’s Disease space. You might have read about AC Immune‘s ‘$700M IPO’ and thought, “gee, that can’t be right – that sum is roughly half of the total from all European companies […]

September 26, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 26 Sep 2016

Terrible Turing hasn’t given up on Toxoplasmosis (or its Karma)

The biopharmaceutical company’s Swiss division just published computational studies aiming to improve Daraprim, after its former CEO, Martin Shkreli, attempted to justify the scandalous 5000% price hike as a boost for its R&D. A little over a year ago, Martin Shkreli, founder and then-CEO of Turing Pharmaceuticals, hiked the price of a common medication for toxoplasmosis by […]

September 26, 2016 - 3 minutesmins - By Evelyn Warner

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Boehringer buys a €210M ticket to Virus-based Immuno-Oncology

Interview: This Biotech Could Have the First HIV Cure on the Market

Titans in Gene Therapy and TCRs make a Massive Deal

Debunking the Immuno-Oncology Hype: is it as good as it sounds?

Biotech is one of the biggest Employers in Europe

Little Biotechs manoeuvre to outfox Big Pharma in Immuno-Oncology

ITW: Prexton Therapeutics CEO explains Development of new Parkinson’s Drug

Another “Almost” against Alzheimers: Lundbeck’s Phase III Flop

A Colony from a single-cell? All possible with Takara Bio

It’s Biotech Week! What’s Up in Europe?

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers

Terrible Turing hasn’t given up on Toxoplasmosis (or its Karma)

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!